D121/OlPC/oleylphosphocholine is a member of the alkylphosphocholines family. Alkylphosphocholines are known for their antiproliferative action. The different analogs have high potential as treatment candidates against multiple diseases including cancer, parasitic infections, bacterial infections, fungal diseases, multiple sclerosis and psoriasis. Oleylphosphocholine is considerd to be a new chemical entity and a promising candidate to respond to critical unmet medical needs : Leishmaniasis, Chagas Disease, Cryptosporidium infection and invasive fungal infections (IFIs).

Leishmaniasis , Chagas Disease and Cryptosporidium infection are parasitic infections and IFIs are a group of fungal infections that primarily affect immunocompromised patients. All are potentially lethal if not treated well and are characterized by urgent unmet medical needs as current treatment options for these diseases are largely inadequate. Current pre-clinical data show that oleylphosphocholine has a significantly bigger therapeutic window than the current state-of-the-art treatment against Leishmaniasis. Furthermore, convincing in vitro and in vivo preclinical results on the effectiveness of oleylphosphocholine against Chagas Disease and IFIs have been documented, and show the potential of this compound to treat these indications.

The first three indications are orphan diseases and the latter one is a potential block buster. With an orphan-drug market strategy, oleylphosphocholine can become a major block-buster while being developed at limited costs and limited risks. In this way, both the commercial potential as well as the curative potential for these highly neglected patients is fully leveraged.


NCE Indication preclinical Phase I Phase II Phase III Registration /Market
D121 Cutaneous and muco- leishmaniasis          
  Visceral leishmaniasis          
  Chagas disease          
  Antifungal infection